QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports Long-Term Phase II GelrinC(R) Cartilage Repair Results Published in Cartilage Journal
Regentis Biomaterials (NYSE American: RGNT) today announced publication of long-term follow-up results from its completed Phase II clinical trial of GelrinC(R) in the peer-reviewed journal Cartilage, highlighting durable cartilage regeneration at 24 months. The study reported a mean MOCART score of 88.8 out of 100 across all lesions, with osteochondral lesions achieving a mean score of 94, supporting evidence of near-complete structural repair and maturation toward hyaline-like cartilage based on quantitative MRI assessments. To view the full press release, visit https://ibn.fm/IyWli About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that…
